User profiles for P. Kuna
Piotr KunaProfessor of Medicine, Medical University of Lodz, Poland Verified email at umed.lodz.pl Cited by 38500 |
Allergic rhinitis and its impact on asthma (ARIA) 2008
Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure by an
immunoglobulin E (IgE)-mediated inflammation of the membranes lining the nose (1). It was …
immunoglobulin E (IgE)-mediated inflammation of the membranes lining the nose (1). It was …
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs
…, L Grouse, T Haahtela, N Khaltaev, P Kuna… - Journal of Allergy and …, 2012 - Elsevier
Allergic rhinitis (AR) and asthma represent global health problems for all age groups.
Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on …
Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on …
Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development …
The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease
and depends on many factors. Grading of Recommendations Assessment, Development …
and depends on many factors. Grading of Recommendations Assessment, Development …
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
…, PW Hellings, L Klimek, S Kowalski, P Kuna… - Journal of Allergy and …, 2017 - Elsevier
Background Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of
life and school and work performance and is a frequent reason for office visits in general …
life and school and work performance and is a frequent reason for office visits in general …
[HTML][HTML] Oral glucocorticoid–sparing effect of benralizumab in severe asthma
… in the oral glucocorticoid doses in the placebo group (P<0.001 for both comparisons). The
odds of … 1.83, P=0.003), and benralizumab administered every 8 weeks resulted in an annual …
odds of … 1.83, P=0.003), and benralizumab administered every 8 weeks resulted in an annual …
International consensus on (ICON) pediatric asthma
Asthma is the most common chronic lower respiratory disease in childhood throughout the
world. Several guidelines and/or consensus documents are available to support medical …
world. Several guidelines and/or consensus documents are available to support medical …
Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009
…, L Fontana, CH Katelaris, R Kaulsay, P Kuna… - World Allergy …, 2009 - Springer
Sublingual immunotherapy (SLIT) has gained wide accep-tance in many European countries
and has raised the level of interest in immunotherapy among practicing allergists and …
and has raised the level of interest in immunotherapy among practicing allergists and …
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
…, P Staubach, T Jakob, RG Stirling, P Kuna… - Journal of Allergy and …, 2013 - Elsevier
… Treatment differences were presented as least squares means (LSMs), along with
corresponding 95% CIs and P values. Analysis of additional end points evaluating change from …
corresponding 95% CIs and P values. Analysis of additional end points evaluating change from …
Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations
P Kuna, MJ Peters, AI Manjra, C Jorup… - … journal of clinical …, 2007 - Wiley Online Library
This randomised, double‐blind, 6‐month study compared budesonide/formoterol for
maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/…
maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/…
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
…, ER Bleecker, E Pizzichini, P Kuna… - The Lancet …, 2014 - thelancet.com
Background Persistent eosinophilic airway inflammation in asthma increases the risk of
exacerbations. In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of …
exacerbations. In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of …